I hereby consists this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on

December 16, 2002

Frank C. Eisenschenk, Ph.D., Patent Attorney

INFORMATION DISCLOSURE STATEMENT

Examining Group 1636 Patent Application

Docket No. G-044US04DIV Serial No. 10/071,179

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

unknown

Art Unit

1636

Applicant

Lydie Bougueleret

RECEIVED

Serial No.

10/071,179

DEC 3 1 2002

Filed

February 7, 2002

TECH CENTER 1600/2900

Conf. No.

2980

For

Nucleic Acid Encoding A Retinoblastoma Binding Protein (RBP-7) and

Polymorphic Markers Associated with Said Nucleic Acid

**Assistant Commissioner for Patents** Washington, D.C. 20231

#### INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.56, 1.97, AND 1.98

Sir:

In accordance with 37 C.F.R. § 1.56, the references on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

The undersigned hereby certifies that each item of information contained in this statement was cited in a communication from a foreign patent office in a counterpart foreign application.

2

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO/SB/08 with initials or other appropriate marks. If any additional fee is required, or to credit any overpayment, please use Deposit Account No. 19-0065.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.56, 1.97, and 1.98 are met by the foregoing statements.

Respectfully submitted,

Frank C. Eisenschenk

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100 Fax No.: 352-372-5800

Address: Saliwanchik, Lloyd & Saliwanchik

A Professional Association 2421 N.W. 41<sup>st</sup> Street, Suite A-1 Gainesville, FL 32606-6669

FCE/dt

Attachments: Form PTO/SB/08A & B (4 pages)

Copies of references cited

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Complete if Known Substitute for form 1449A/PTO **Application Number** 10/071,179 INFORMATION DISCLOSURE Filing Date February 7, 2002 STATEMENT BY APPLICANT First Named Inventor Lydie Bougueleret Art Unit (use as many sheets as necessary) 1636 **Examiner Name** of **Attorney Docket Number** Sheet 4 G-044US04DIV

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. 1	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	U1	US-5,795,714	08/18/1998	Cantor et al.,			
	U2	US-					
	U3	US-			RECEIL		
	U4	US-			OLIV		
	U5	US-			DEC 3 1 200		
	U6	US-			TECH CENTED 4		
	U7	US-			1600 C		
	U8	US-					
	U9	US-					

	FOREIGN PATENT DOCUMENTS					
		Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,	
Examiner Initials*	Cite No. <sup>1</sup>	Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	F1	WO 93/23539	05/13/1993	Dana-Farber Cancer Institute		
	F2	WO 94/12521	11/19/1993	University of Texas		
	F3	WO 95/05392	08/11/1994	University of Texas		
	F4	WO 96/25494	04/18/1995	The Medical Research Council		
	F5	WO 96/28568	05/24/1995	University of Michigan		
	F6	WO 99/04265	07/15/1998	Ludwig Institute for Cancer Research		
	F7					
	F8				- 1	

Examiner	Date	
Signature	 Considered	<b>_</b>

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the Applicant is to place a check mark here if appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. English language Translation is attached.



Sheet

### RECEIVED



DEC 3 1 2002

## TECH CENTER 1600/2900 Approved for use through 10/31/2002. OMB 0651-0031

PTO/SB/08B (10-01)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449B/PTO

#### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

4

Complete if Known			
Application Number 10/071,179			
Filing Date	February 7, 2002		
First Named Inventor	Lydie Bougueleret		
Group Art Unit	1636		
Examiner Name			
Attorney Docket Number	G-044US04DIV		

	_	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	R1	ADAMS, M.D. et al., "Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence", <i>Nature</i> , 1995, Vol. 377, (6547 Suppl), pp. 3-174, Accession no. AA296993.	
	R2	BERENDSEN, Herman, "A Glimpse of the Holy Grail?", Science, 1998, Vol. 282, pp. 642-643.	
	R3	CAO, J. et al., "RBP1L1, a Retinoblastoma-Binding Protein-Related Gene Encoding an Antigenic Epitope Abundantly Expressed in Human Carcinomas and Normal Testis", J. Natl Cancer Inst., 2001, Vol. 93, No. 15, pp. 1159-1165.	
	R4	FATTAEY, A., et al., "Characterization of the retinoblastoma binding proteins RBP1 and RBP2", Oncogene, 1993, Vol. 8, pp. 3149-3156, Pub: MacMillan Press, Ltd.	
	R5	GALPERIN, M. et al., "Who's your neighbor? New Computational approaches for functional genomics", Nature Biotechnology, 2000, Vol. 18, pp. 609-613.	
	R6	HELIN, K. et al., "A cDNA Encoding a pRB-Binding Protein with Properties of the Transcription Factor E2F", Cell, 1992, Vol. 70, pp. 337-350.	
	R7	HILLIER L. et al.,, "Generation and Analysis of 280,000 human expressed sequence tags", Genome Res., 1996, Vol. 6, No. 9, pp. 807-828, Accession no. T61718.	
	R8	HILLIER L. et al., "Generation and Analysis of 280,000 human expressed sequence tags", Genome Res., 1996, Vol. 6, No. 9, pp. 807-828, Accession no. AA082927.	
	R9	HILLIER L. et al., "The WashU-Merck EST Project", Unpublished - EMBL Sequence Database, April 12, 1995, Accession no. R14337.	
	R10	HILLIER L. et al., "The WashU-Merck EST Project", Unpublished - EMBL Sequence Database, April 24, 1995, Accession no. R27405.	
	R11	HILLIER L. et al., "The WashU-Merck EST Project", Unpublished - EMBL Sequence Database, May 22, 1995, Accession no. R40663.	
	R12	HILLIER L. et al., "The WashU-Merck EST Project", Unpublished - EMBL Sequence Database, May 22, 1995, Accession no. R44970.	
	R13	HILLIER L. et al., "The WashU-Merck EST Project", Unpublished - EMBL Sequence Database, June 23, 1995, Accession no. H08612.	

	·— · · · · · · · · · · · · · · · · · ·		
Examiner		Date	
Signature		Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.




Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.




Sheet

# RECEIVED



# TECH CENTER 1600/2900



Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

3

of

4

Complete if Known		
Application Number	10/071,179	
Filing Date	February 7, 2002	
First Named Inventor	Lydie Bougueleret	
Group Art Unit	1636	
Examiner Name		
Attorney Docket Number	G-044US04DIV	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R14	HILLIER L. et al., "The WashU-Merck EST Project", Unpublished - EMBL Sequence Database, August 16, 1995, Accession no. H38607.	
-	R15	HILLIER L. et al., "The WashU-Merck EST Project", Unpublished - EMBL Sequence Database, August 16, 1995, Accession no. H39516.	
	R16	HILLIER L. et al., "The WashU-Merck EST Project", Unpublished - EMBL Sequence Database, October 10, 1996, Accession no. W37603.	
	R17	HILLIER L. et al., "The WashU-Merck EST Project", Unpublished - EMBL Sequence Database, October 15, 1996, Accession no. W67770.	
	R18	HILLIER L. et al., "The WashU-Merck EST Project", Unpublished - EMBL Sequence Database, October 15, 1996, Accession no. W67771.	
	R19	HILLIER L. et al., "The WashU-Merck EST Project", Unpublished - EMBL Sequence Database, October 17, 1996, Accession no. W84531.	
_	R20	HILLIER L. et al., "The WashU-Merck EST Project", Unpublished - EMBL Sequence Database, May 22, 1996, Accession no. W44777.	
	R21	HILLIER L. et al., "The WashU-Merck EST Project", Unpublished - EMBL Sequence Database, June 16, 1996, XP002121367, Accession no. W67771.	
	R22	HILLIER L. et al., "The WashU-Merck EST Project", Unpublished - EMBL Sequence Database, April 29, 1997, XP002121368, Accession no. AA399016.	
	R23	HILLIER L. et al., "The WashU-Merck EST Project", Unpublished - EMBL Sequence Database, May 16, 1997, Accession no. AA399016.	
	R24	HILLIER L. et al., "The WashU-Merck EST Project", Unpublished - EMBL Sequence Database, August 8, 1997, Accession no. AA479433.	
	R25	HILLIER L. et al., "The WashU-NCI human EST Project", Unpublished - EMBL Sequence Database, March 9, 1998, Accession no. AA167428.	
	R26	HILLIER L. et al., "The WashU-NCI human EST Project",, Unpublished - EMBL Sequence Database, March 9, 1998, Accession no. AA169631.	

Examiner	Date
Signature	Considered


<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.



Sheet



DEC 3 1 2002

TECH CENTER 1600/2900

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Under the control number.

> Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

> > (use as many sheets as necessary)

of 4

Complete if Known			
Application Number	10/071,179		
Filing Date	February 7, 2002		
First Named Inventor	Lydie Bougueleret		
Group Art Unit	1636		
Examiner Name			
Attorney Docket Number	G-044US04DIV		

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, joumal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
	R27	KAELIN, W. et al., "Expression Cloning of a cDNA Encoding a Retinoblastoma-Binding Protein with E2F-like Properties", Cell, 1992, Vol. 70, pp. 351-364, Pub: Cell Press.				
	R28	NEUMAN, E. et al., "Structure and Partial Genomic Sequence of the Human E2F1 gene", Gene, 1996, 173:163-169, Pub: Elsevier Science B.V.				
	R29	OTTERSON, G. et al., "Alternative splicing of the RBP1 gene clusters in an internal exon that encodes potential phosphorylation sites", Oncogene, 1993, Vol. 8, pp. 949-957, Pub: MacMillan Press Ltd.				
	R30	QLAN, Y. et al., "A retinoblastoma-binding protein related to a negative regulator of Ras in yeast", <i>Nature</i> , 1993, Vol. 364, pp. 648-652.				
	R31	SAKAI, Y. et al., "cDNA Sequence and Chromosomal Localization of a Novel Human Protein, RBQ-1 (RBBP6), That Binds to the Retinoblastoma Gene Product", <i>Genomics</i> , Vol. 30, pp. 98-101 (1995), Pub: Academic Press, Inc.				
	R32	SMITH, D.R., "Sequencing of Human Chromosome 10", Genome Therapeutics Corporation (Submitted), December 4, 1998, Accession no. AC006107.				
	R33	TAKAHASHI, T. et al., "Cytotoxic T lymphocytes that recognize decameric peptide sequences of retinoblastoma binding protein 1 (RBP-1) associated with human breast cancer", British Journal of Cancer, 1999, Vol. 81, No. 2, pp. 342-349, Pub: Cancer Research Campaign.				
	R34	UNKNOWN, "National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index", Unpublished - EMBL Sequence Database, August 13, 1997, Accession no. AA262427.				
	R35	UNKNOWN, "National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index", Unpublished - EMBL Sequence Database, August 15, 1997, Accession no. AA279595.				
	R36	UNKNOWN, "National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index", Unpublished - EMBL Sequence Database, August 15, 1997, Accession no. AA485189.				
. <u>-</u>	R37	UNKNOWN, "National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index", Unpublished - EMBL Sequence Database, January 29, 1998, Accession no. AA772654.				
	R38	UNKNOWN, "National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index", Unpublished - <i>EMBL Sequence Database</i> , April 7, 1998, Accession no. AA830588.				
	R39	UNKNOWN, "National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index", Unpublished - EMBL Sequence Database, December 31, 1998, Accession no. AA772654.				

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.